Background: Phytoestrogens consumption is targeted as a possible way to achieve hormonal permeation in postmenopausal women. However, their health effect could depend on their bioavailability.
Introduction
Most observational studies have provided evidence that postmenopausal women consuming the highest amounts of soya foods (and hence isofl avones) have the highest bone mineral density (BMD) (Setchell and Lydeking-Olsen, 2003) . The effects on bone markers are confl icting (Alekel et al. 2000; Scheiber et al. 2001) . In fact, Setchell et al. (2002) have hypothesised that intestinal metabolism of isofl avones could be the most important clue to the clinical effi cacy of soya foods in preventing osteopenia.
Almost all phytoestrogens in food exist predominantly as glycosides, such as genistin and daidzin. This glycoside bond has to be hydrolysed for intestinal absorption to occur (Murkies et al. 1998) . Hydrolysis is extremely effi cient and occurs along entire length of the intestinal tract by the action of both the brush border membrane and the bacterials β-glucosidases, wich are active from relatively early in life. Glucosidases of intestinal bacteria such as lactobacilli, bifi dobacteria and bacteroides (Xu et al. 1995) were involved in this process. After deglycosylation, the isofl avonoid aglycons can undergo further fermentation by colonic microfl ora to produce a number of metabolites prior to absorption (Setchell, 1998) . Chang and Nair (1995) have shown conversion of daidzein to dihydrodaidzein and equol by human faecal bacteria. The clinical effectiveness of soy proteins in general health is believed to be a function of the ability to biotransform soy isofl avones to the more potent estrogenic isofl avone, equol . This metabolite has a longer half life and a much higher affi nity for the estrogen receptor, than other isofl avones and has the highest antioxidant capacity among isofl avones . However, because of a great inter-individual variation in the ability of the bacteria to produce equol, about 30%-50% of the adult population does not excrete this metabolite in urine, when challenged daily with soy foods (Rowland et al. 1999; Lampe et al. 1998) . In a 2-year study carried out in post-menopausal women drinking 500 ml of soymilk either with or without isofl avones, greater effects on bone health were elicited when volunteers were able to produce equol .
In addition, it has been established that dietary fi ber intake may exert a major infl uence on isofl avones metabolism, by modulating intestinal microfl ora (Xu et al. 1995) . In this light, prebiotics (short-chain fructo-oligosaccharides (scFOSs)), a mixture of indigestible and fermentable carbohydrates known to stimulate growth of benefi cial intestinal bacteria such as bifi dobacteria, are very interesting (Bouhnik et al. 1996) . They may increase β-glucosidase activity in the large intestine, leading to enhancement absorption of these compounds (Uehara et al. 2001) . The clearance of isofl avones is thus prolonged.
As phytoestrogens bioavailability could be improved by modulating intestinal microfl ora, the present study was undertaken to investigate whether isoflavones associated with pre-or probiotics may prevent the increase bone turnover in postmenopausal women. We evaluate this potential effect on specifi c biochemical markers of bone formation (bone specifi c alkaline phosphatise) phosphatase and bone resorption (Deoxypyridinoline) which are useful in monitoring the progression of disease in an individual because the response to therapy is earlier and more pronounced than changes in BMD (Delmas, 2000) .
Subjects and Methods

Volunteers
This randomised, double-blind, placebo-control study (n°: AU429) was approved by the local ethical committee from Auvergne (CCPPRB, Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale).
Thirty-nine healthy postmenopausal women aged 47 to 73 years old (60.4 ± 7.1) (Fig. 1) were recruited for the study, menstrual bleeding within 12 months (shown by LH levels and FSH levels between 25.8 and 134.8 UI/L). Among these, twelve were in early menopause, less than 7 years.
Subjects were selected after a phone questionnaire, interviews, and health screen. Exclusion criteria included strict vegetarian and vegan, high fi bre and high soy diets, antibiotics or hormonal replacement therapy within 3 months, menstrual bleeding within 12 months, history of chronic digestive disorders, allergy for milk protein or soy, laxatives taken and severe constipation. Selected volunteers had not undergone surgically induced menopause or surgery of digestive tract. Subjects did not take nutritional supplements the 3 months prior to the study or any medication known to affect bone metabolism. The participants were willing to take dairy products and have not been involved in any clinical trial 6 months before entering this study.
Volunteers underwent a screening visit that included a health history questionnaire, electrocardiogram and routine blood chemistry. At this visit, they were given 5 d food record forms to complete at home. The records were subsequently analysed using a software program, Geni version 6.0 (société micro 6, Les Villers Nancy, France). Daily mineral calcium intakes (mg/d) were 848 ± 90 and 896 ± 60 in early and later postmenopausal women, respectively. Daily vitamin D intakes (μg/j) were 1.87 ± 0.50 and 1.32 ± 0.20 in early and later postmenopausal women, respectively.
Experimental design and diet (Fig. 1 ) At recruitment, women were asked not to eat soy or soy products for 2 wk (run-in period) before the study started and for the whole duration of the study. Except for this restriction, all women maintained their usual feeding habits. After the run-in period and throughout the 2-month challenge, they received 1 gelifi ed milk (Danone Vitapole) and 1 cereal bar (Nutrition and Santé), twice a day, which provided together 100 mg/d of isofl avones aglycon equivalents (Prevastein ® HC, Eridania Béghin-Say). Isoflavones (genistin 55%-75%, daidzin 20%-40%, glycitin 1%-5%) were incorporated in jelly milks and cereal bars, supplying 25 mg of isoflavones each. After this first Run-in period experimental period (d0 to d30), the participants were randomised according to their urinary equol production levels, measured in blood and urine samples using immunological methods at d5 (Molis et al. 1996) into three groups: soy, soy + prebiotics or soy + probiotics. So, each group included high (Ͼ9 μmol/24 h, n = 16), low (Ͻ5 μmol/24 h, n = 8) and non-producers of equol (100 μmol/24 h, n = 15). During this second month (d30 to 60), gelifi ed milk and cereal bars provided 100 mg/d of isofl avones alone for the control group (n = 12), 100 mg of isofl avones combined with 125 mg of yogurt cultures (Streptococcus thermophilus, Lactobacillus bulgaricus, and ∼10 9 viable cells of the probiotic strain Bifidobacterium animalis DN-173 010 ) for the probiotic group (n = 14), or 100 mg of isofl avones combined with 7 g of shortchain fructooligosaccharides (scFOS) (95% ± 2% sc-FOS and 5% ± 2% glucose, fructose and saccharose; Actilight, Béghin-Meiji Industries, Thumeries, France) for the prebiotic group (n = 13). During this second month, the soy group was considered as the control group.
Blood sampling was performed in the morning, after an over-night fasting, at d0 and every 15 days thereafter to assess bone specific alkaline phosphatase (bALP) (Garnero and Delmas, 1999) and isofl avones (daidzein, genistein and equol) (Bennetau-Pelissero et al. 2000) . Twenty-four hour urine samples were obtained from the volunteers at the same time points, during the study to analyse deoxypyridinoline (DPD) (Robins, 1994) . In addition, a 24 h urine collection was organised at d5 and urine samples were analysed for equol production.
Biochemical analysis
Plasma phytoestrogen concentrations plasma genistein, daidzein and equol concentrations were measured by ELISA (Bennetau-Pelissero et al. 2000) . The sensitivity of the method was 35, 40 and 10 nmoles for genistein, daidzein and equol, respectively. The intra and inter assay variations measured on ten different assays were 4.8 and 13.1% for genistein, 5 and 12.8% for daidzein, then 5 and 13.6%, for equol.
Marker for osteoblastic activity
Serum bone specifi c alkaline phosphatase (bALP) was measured by the Tandem-R Ostase immunoradiometric assay (IRMA, Beckman Coulter Inc., Fullerton, CA, U.S.A) The intra-and interassay variations were less than 6.7 and 8.1%, respectively, across the working range (0-120 μg/l).
Marker of bone resorption
Deoxypyridinoline (DPD) in urine was assessed by a radioimmunoassay kit (Pyrilinks-D RIA kit, Metra Biosystems Inc., Mountain view, CA, U.S.A). The intra-and interassay variations were 6% and 7.5%, respectively. Results are expressed as nmoles DPD per mmoles of creatinine (Robins, 1994) .
The urinary creatinine assay (Kit Bio MERIEUX SA, Marcy-l'Etoile, France) is based on a modifi ed Jaffe's method, in which picric acid forms a coloured solution in the presence of creatinine (Cook, 1975) .
Statistical analysis
The sample size has been calculated to detect differences in plasma levels of total IF between groups consuming different food matrixes equal to ½ SD (0.15 μmol/L), observed in 12 adult women after a single dose of 126 mg IF administered as soy milk (Xu et al. 1994) . A total of 35 subjects is required to detect differences between groups with 80% power, signifi cance level set at 0.05. Assuming a 10% drop out rate, 39 volunteers have been involved in the study.
Results are expressed as means ± SEM for continuous data and as count (n) and frequencies (%) for qualitative data. All data were analysed using the Graphpad Instat software (Microsoft, San Diego, CA, U.S.A). Statistical tests have been chosen according to the data distribution (KolmorogovSmirnov test). ANOVA was fi rst performed to test for any signifi cant differences among groups. When signifi cant (P Ͻ 0.05), the Student-Newman-Keul's multiple comparison test was applied to determine the specifi c differences between means. If not, nonparametric analyses were performed as a Kruskall-Wallis test. If it indicated a signifi cant difference among groups (P Ͻ 0.05), the MannWhitney U test was used to determine specifi c differences. The signifi cant level was set at P Ͻ 0.05 for all statistical analysis.
Results
Body weight (g) and body mass index (BMI; g/cm 2 ) did not change significantly during the study (data no shown). Those parameters were not clinically modulated by experimental diets.
Plasma IF levels
As shown in Figure 2 , plasma concentration profi les of genistein, daidzein and equol, over the experimental period (d0 to 60) allowed validation of isofl avones consumption. In the control group, values (ng/ml) were undetectable at baseline and reached, a plateau as soon as 15 days (426 ± 50.3) and stayed relatively unchanged at d60. Moreover, among volunteers, 56.4% were equol producers, although only 50% of them reached levels higher than 200 ng/ml.
In the prebiotic group (during the second month of the study), plasma concentrations (ng/ml) of genistein, daidzein and equol remained unchanged, compared to the soy group (genistein: 558.56 ± 74.40; daidzein: 322.30 ± 62.64; equol: 181.38 ± 39.11). Regarding the probiotics group, a signifi cantly (p Ͻ 0.05) 24% increase in plasma genistein concentrations was demonstrated from d30 to 60. Equol levels even tended to be higher at d60 (263.85 ± 99.6), whereas plasma daidzein stayed unchanged (417.61 ± 84.74).
In the subgroup of equol producers, the trend towards higher equol levels (ng/ml) elicited by probiotics consumption became significant at day 60 (428.88 ± 132.39, P Ͻ 0.05 compared to 194.14 ± 43.42, in equol producers from the soy group).
Bone turnover biomarkers (Figs. 3 and 4)
For results presentation, we divided the subjects of our study into 2 subgroups, according to menopausal status. It is well known that fi rst 5 years after the onset of menopause are marked predominantly by hormonal disturbances. Moreover the rate of bone loss is most rapid in the early postmenopausal period and subsequently begins to level off by 5 years menopause (Pouilles et al. 1993) .
None correlation was observed between the capacity to produce equol and bone markers.
Bone biomarkers were expressed as means ± SEM changes from baseline (%). An 8 (±5)% increase of bone alkaline phosphatase was elicited on d30, in the control group, compared to initial values, then, return to basal levels (1.76% ± 5.49%) on d60. On d60, this parameter was not signifi cantly modulated by pre-or probiotics (−1.3% ± 4.44% changes in the prebiotics group; 10.3% ± 8. Figure 2 . Plasma A) genistein, B) daidzein and C) equol concentrations in postmenopausal women who have been given soy isofl avones for 2 months at the dose of 100 mg aglycones per day, or soy isofl avones at the same dose for 2 months, together with probiotics for the last month (125 mg of yoghurt culture including Streptocccus thermophilus and Lactobacillus bulgaricus and Bifi dobacterium animalis), or soy isofl avones at the same dose for 2 months, together with prebiotics for the last month (7 g of short chain Fructooligosaccharides). Signs in white indicate plasma values of equol in women who were considered as equol producers (levels higher than 200 ng/ml). *, P Ͻ 0. Figure 4. Markers for bone metabolism throughout the experimental period in 1) early postmenopausal women and 2) late postmenopausal women given soy isofl avones for 2 months at the dose of 100 mg aglycones per day, or soy isofl avones at the same dose for 2 months, together with probiotics for the last month (125 mg of yoghurt culture including Streptocccus thermophilus and Lactobacillus bulgaricus and Bifi dobacterium animalis), or soy isofl avones at the same dose for 2 months, together with prebiotics for the last month (7 g of short chain Fructooligosaccharides). *, P Ͻ 0.05 compared to the isofl avones group. Results are expressed as a % change from baseline values at day 60. Values are means ± SEM. A) Urinary deoxypyridinoline levels, a marker for bone resorption, B) Plasma bone specifi c alkaline phosphatase values, a marker for bone formation.
changes in the probiotics group). However, when women within early menopause (Ͻ7 years since last menses) were considered, a trend towards higher levels of ALP with probiotics consumption was observed (22% increase, compared to 3% in the soy group at d60). On the contrary, as far as women within late menopause (Ͼ7 years since last menses) are concerned, no variation were observed between each group. In the control group, a −5 (±5)% decrease urinary DPD excretion was observed on d30 and then returned to initial values (%) at d60 (15.5 ± 4.9).
Pre-or probiotics consumption improved this marker. At d60, they respectively elicited a 13% and 12% decrease, compared to control group, even though no variation was observed compared to d0. In women within early menopause, this pattern was similar and a 23% decrease was observed in the prebiotics group compared to the control group (P Ͻ 0.02). In late postmenopausal women, the effect of pre-or probiotics was a 25% decrease was reached in the probiotics group compared to the control group (P Ͻ 0.05).
Discussion
In the present investigation, doses of phytoestrogens (100 mg/day) given to postmenopausal women have been calculated on estimated dietary isofl avones intakes in the Asian countries where a lower incidence of hip fractures was observed. This level of intake was associated with a signifi cant increase in plasma isofl avones (Fig. 1) , indicating complete compliance with soy consumption.
More interestingly, increasing bacteria involved in the metabolism of isofl avones could maximise potential health benefi ts of those phytoestrogens. Recently, Zafar et al. (2004) have observed in ovx rats that inuline, a prebiotic, could modulate equol production from the daidzein in the soy isofl avones suggesting a shift in metabolism of the isofl avones. In our experimental conditions, plasma equol concentrations were not modifi ed in the prebiotics group, compared to the control group. Actually, results from a population-based family study suggest that the ability to harbour the daidzein-metabolising bacteria, then contributing to the equol-producer phenotype in humans, might be under some degree of genetic control (Frankenfeld et al. 2004) . Indeed prevalences of equol producers and o-DMA producers are approximately 30%-50% and 80%-90%, respectively, and limited observations have suggested that these daidzein-metabolising phenotypes are stable within individuals over time (Frankenfeld, 2005) . Besides, probiotics, live microbials which benefi cially affects the host animal by improving its intestinal microbial balance, can be benefi cial to health, as well. In our experimental conditions, plasma genistein and equol levels were signifi cantly higher, after probiotics consumption, compared to the soy group at the end of the supplementation.
Although some dietary intervention trials have shown that phyto-estrogens-rich diets improve BMD Morabito et al. 2002) , the effects on bone markers are however less clear. In postmenopausal women, results of studies on isofl avone supplementation with various doses for 1.5 to 3 months were confl icting (Scambia et al. 2000; Scheiber et al. 2001; Uesugi et al. 2002) . In the present experiment, only a trend towards a higher osteoblastic activity was observed after 30 days IF daily consumption and resorption activity tended to decrease at d30 and to increase after 60 days of supplementation (Fig. 3) . Therefore, in our experimental conditions, it can be ruled out that a two months supplementation of 100 mg of isofl avones in 39 post-menopausal women has no signifi cant effect on bone markers. This lack of effect could be explained by the wide range (1-37 years) in the menopause duration. Actually, if we consider only the volunteers in early menopause (Ͻ7 years), the bone resorption activity was higher in the soy group at d60 and ALP was lower in early postmenopausal women, compared to all volunteers. Similarly, reduction of bone resorption activity has been shown after 2.5 to 3 months of isofl avone consumption in peri-or postmenopausal women (Uesugi et al. 2002) . These results were in agreement with those of Nordin et al. (1990) . Bone loss is more rapid in early menopause (11.3%) than in the following decade (2.3% and 1.5%). On another hand, in late postmenopausal women, resorption was more important than that observed in early postmenopausal women. These data are in accordance with these obtained by Garnero et al. (1996) in elderly women, a high bone turnover rate was being associated with a low bone mass. Moreover, Cheong et al. (2007) showed that soy protein containing up to 135.5 mg isofl avones/day for 50 days, did not suppress bone resorption in late postmenopausal women (Ͼ6 years since menopause).
Regarding the impact on skeletal metabolism, neither pro-nor prebiotics elicited any signifi cant modulation of bone formation. In postmenopausal women (50-70 aged) Tahiri et al. (2001) have shown not signifi cant changes of bone turnover after 5 weeks scFOS treatment, but, a trend towards a higher activity was observed in women within less than 7 years of menopause. Concerning bone resorption, both pro-and prebiotics were associated with improvement of DPD values and in early postmenopausal women, the effect of sc-FOS was even intensified. Those results (Figs. 3 and 4) are consistent with previous data from animal experiment. In ovariectomised mice (Ohta et al. 2002) or rats (Mathey et al. 2004 ), oligofructose consumption has been shown to exacerbate the bone sparing effect of isofl avones by slowing down bone resorption. These protective effects cannot be totally explained by equol production, because this parameter was only increased in the probiotics group. Moreover, Frankenfeld et al. (2006) did not observe a difference in BMD in relation to equol-producer phenotype. Of course, a concomitant trend towards an increase in mineral bioavailability and oestrogen mimetic effect cannot be ruled out (Scholtz-Ahrens et al. 2001) . Indeed, according to the data published by Abrams et al. (2005) , a mixture of chicory long-chain inulin and oligofructose is able to increase calcium absorption in volunteers and to impact markers of bone turnover.
In late postmenopausal women, bone markers were not modified by prebiotics. However, probiotics seemed to elicit a decrease in bone resorption, compared to the control group, without signifi cant variation of formation. Levels of DPD in prebiotics group were decreased compared to control groups. Similarly, Holloway et al. (2007) showed an initial transient decrease of DPD after 3 weeks of supplementation with a mixture of chicory oligofructose and long-chain inulin (synergy 1) in women (10 years past the onset of menopause). Nevertheless, they observed a signifi cant increase in Ca absorption, relative to the group placebo after 6 weeks of treatment, while the markers for bone turnover did not signifi cantly change. Of course, it remains to be demonstrated that the effi cacy of these prebiotics on calcium absorption were benefi ts for bone health.
Our study has several limitations, one, given the small sample of women in each supplemented group and in the early or late postmenopausal subgroup. Secondly, a long-term study in which bone density is the central biomarker may help to validate the potential benefi ts of pre-or probiotic consumption combined with soy isoflavone intake.
In conclusion, under the conditions of the present study, addition of pre-or probiotic to a diet providing isofl avones is able to improve parameters of bone turnover in early menopause.
